483 related articles for article (PubMed ID: 28747358)
1. Urinary renin-angiotensin markers in polycystic kidney disease.
Salih M; Bovée DM; Roksnoer LCW; Casteleijn NF; Bakker SJL; Gansevoort RT; Zietse R; Danser AHJ; Hoorn EJ
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F874-F881. PubMed ID: 28747358
[TBL] [Abstract][Full Text] [Related]
2. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
[TBL] [Abstract][Full Text] [Related]
3. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
[TBL] [Abstract][Full Text] [Related]
4. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
van den Heuvel M; Batenburg WW; Jainandunsing S; Garrelds IM; van Gool JM; Feelders RA; van den Meiracker AH; Danser AH
J Hypertens; 2011 Nov; 29(11):2147-55. PubMed ID: 21941204
[TBL] [Abstract][Full Text] [Related]
5. Urinary Angiotensinogen and Renin Excretion are Associated with Chronic Kidney Disease.
Juretzko A; Steinbach A; Hannemann A; Endlich K; Endlich N; Friedrich N; Lendeckel U; Stracke S; Rettig R
Kidney Blood Press Res; 2017; 42(1):145-155. PubMed ID: 28395289
[TBL] [Abstract][Full Text] [Related]
6. A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease.
Kocyigit I; Yilmaz MI; Unal A; Ozturk F; Eroglu E; Yazici C; Orscelik O; Sipahioglu MH; Tokgoz B; Oymak O
Am J Nephrol; 2013; 38(3):218-25. PubMed ID: 23988725
[TBL] [Abstract][Full Text] [Related]
7. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
Persson F; Lu X; Rossing P; Garrelds IM; Danser AH; Parving HH
J Hypertens; 2013 Aug; 31(8):1646-52. PubMed ID: 23743807
[TBL] [Abstract][Full Text] [Related]
8. Urinary angiotensinogen, related factors and clinical implications in normotensive autosomal dominant polycystic kidney disease patients.
Kurultak I; Sengul S; Kocak S; Erdogmus S; Calayoglu R; Mescigil P; Keven K; Erturk S; Erbay B; Duman N
Ren Fail; 2014 Jun; 36(5):717-21. PubMed ID: 24625116
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease.
Tiryaki Ö; Usalan C; Sayiner ZA
Ren Fail; 2016; 38(2):222-7. PubMed ID: 26707134
[TBL] [Abstract][Full Text] [Related]
10. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
[TBL] [Abstract][Full Text] [Related]
11. Urinary angiotensinogen as a potential biomarker of intrarenal renin-angiotensin system activity in Chinese chronic kidney disease patients.
Xu Z; Xu B; Xu C
Ir J Med Sci; 2015 Jun; 184(2):297-304. PubMed ID: 24664631
[TBL] [Abstract][Full Text] [Related]
12. Interrelationship between renin-angiotensin-aldosterone system and oxidative stress in chronic heart failure patients with or without renal impairment.
Reina-Couto M; Afonso J; Carvalho J; Morgado L; Ronchi FA; de Oliveira Leite AP; Dias CC; Casarini DE; Bettencourt P; Albino-Teixeira A; Morato M; Sousa T
Biomed Pharmacother; 2021 Jan; 133():110938. PubMed ID: 33171402
[TBL] [Abstract][Full Text] [Related]
13. Urinary angiotensinogen level is associated with potassium homeostasis and clinical outcome in patients with polycystic kidney disease: a prospective cohort study.
Kim H; Park S; Jhee JH; Yun HR; Park JT; Han SH; Lee J; Kim SW; Kim YH; Oh YK; Kang SW; Choi KH; Yoo TH;
BMC Nephrol; 2019 Mar; 20(1):104. PubMed ID: 30909873
[TBL] [Abstract][Full Text] [Related]
14. ELISA examining urinary angiotensinogen as a potential indicator of intrarenal renin-angiotensin system (RAS) activity: a clinical study of 128 chronic kidney disease patients.
Zhang XY; Ding XQ; Lv WL; Teng J; Zhong YH
Mol Biol Rep; 2013 Oct; 40(10):5817-24. PubMed ID: 24065527
[TBL] [Abstract][Full Text] [Related]
15. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease.
Mills KT; Kobori H; Hamm LL; Alper AB; Khan IE; Rahman M; Navar LG; Liu Y; Browne GM; Batuman V; He J; Chen J
Nephrol Dial Transplant; 2012 Aug; 27(8):3176-81. PubMed ID: 22399491
[TBL] [Abstract][Full Text] [Related]
16. Chronotherapy with a Renin-angiotensin System Inhibitor Ameliorates Renal Damage by Suppressing Intrarenal Renin-angiotensin System Activation.
Aoki T; Ohashi N; Isobe S; Ishigaki S; Matsuyama T; Sato T; Fujikura T; Kato A; Miyajima H; Yasuda H
Intern Med; 2020; 59(18):2237-2244. PubMed ID: 32938851
[TBL] [Abstract][Full Text] [Related]
17. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin blockade in late autosomal dominant polycystic kidney disease.
Torres VE; Abebe KZ; Chapman AB; Schrier RW; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC; Miskulin DC; Rahbari-Oskoui FF; Grantham JJ; Harris PC; Flessner MF; Moore CG; Perrone RD;
N Engl J Med; 2014 Dec; 371(24):2267-76. PubMed ID: 25399731
[TBL] [Abstract][Full Text] [Related]
19. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC; Rahbari FF; Grantham JJ; Bae KT; Moore CG; Flessner MF
Kidney Int; 2017 Feb; 91(2):493-500. PubMed ID: 27993381
[TBL] [Abstract][Full Text] [Related]
20. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.
Corradi V; Gastaldon F; Caprara C; Giuliani A; Martino F; Ferrari F; Ronco C
Minerva Med; 2017 Feb; 108(1):43-56. PubMed ID: 27701376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
